ZNF217 mRNA expression levels were not correlated with Ki-67 values, neither in the initial breast tumor (pre-treatment) (r = -0.169, P = 0.17), nor in the post-treatment samples (r = -0.026, P = 0.83), nor with the ΔKi-67 values (r = -0.136, P = 0.26), thus ruling out that investigating ZNF217 expression levels was merely a surrogate markers of Ki-67 expression (Spearman test). The gene discussed is ZNF217; the disease is breast neoplasm.